CER budgets heading up in '12

More than half of drug companies plan to increase spending for market-access activities in 2012, including comparative effectiveness research (CER), according to a report from Cutting Edge Information.

Responding to payer demands for outcomes, virtually all drug research companies expect to at least maintain spend across most market-access categories, the benchmarking study showed.

Growth areas include health economics and outcomes research (64% of firms plan to increase funding), as well as patient-reported-outcomes activities, pegged by 57% of respondents for more spend, and CER, which half of firms anticipate upping their spend for.

Across all market access activities studied, pricing teams' budgets will largely remain the same. And according to the study, 73% of companies will hold their pricing budgets steady next year.

Cutting Edge talked to 20 companies for its study, said Elio Evangelista, director of research for the firm.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.